UNSPSC 51342901: Didanosine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3GDH6OH08, chemically known as 2,3-dideoxyinosine & scd4(soluble recombinant protein) but generally known as didanosine, which bears US NIH Compound Identifier 50599. European Medicines Agency schedules Didanosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07104MIG. The term DIDANOSINE is an International Non-Proprietary Name.

UNSPSC 51342901 Didanosine is a Commodity code nominally designating a specific antiretroviral pharmaceutical, but recent state and local procurement activity tagged under this code does not reflect purchases of didanosine itself. Instead, the opportunities show state and local governments soliciting naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program capabilities — a mismatch between the code's nominal scope and actual buying patterns. State and local health agencies, fire departments, and cooperative purchasing alliances are the primary issuing bodies, with procurement mechanisms ranging from invitation-to-bid (IFB) for emergency supplies to requests for information (RFI) for emerging pharmacy benefit program models. The code shows little relevant recent activity aligned to its stated pharmaceutical scope; opportunities that do appear under it address broader pharmaceutical procurement, emergency medical supplies, and pharmacy benefit program innovation rather than antiretroviral drugs specifically.

Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for the Seminole County Community Health Building; the City of Tampa's invitation to bid 26-P-00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, with a 5 percent bid discount reserved for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026. Activity concentrates in Florida and Minnesota, with Texas HHS also active through an RFI exploring direct-to-manufacturer prescription models. The code's current tagging does not appear to serve didanosine procurement specifically and may reflect a classification mismatch in the state and local procurement system.